To assess the ability of FAK blockade to inhibit the colony growth of lung cancer cells in 3-dimensions, a setting that better mimics the potential growth of these cells in vivo, NSCLC cells were embedded in growth factor-reduced BME in complete growth medium and treated with either erlotinib (10μM), PF-228 (either 1 or 5 μM), or the combination of both erlotinib and PF-228. This evidence concerns the gene PTK2 and lung carcinoma.